Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by McGowan, J. P.
Right arrow Articles by Shah, S. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McGowan, J. P.
Right arrow Articles by Shah, S. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 46, 657-668
© 2000 The British Society for Antimicrobial Chemotherapy

Review

Prevention of perinatal HIV transmission during pregnancy

Joseph P. McGowana,c,* and Sanjiv S. Shahb,c

a Division of Infectious Diseases, Bronx-Lebanon Hospital Center, Bronx, New York b Division of Infectious Diseases, Beth Israel Medical Center, New York c Albert Einstein College of Medicine, Bronx, New York, NY, USA

Transmission of the human immunodeficiency virus (HIV) from mother to child can occur in utero, during labour or after delivery from breastfeeding. The majority of infants are infected during delivery. Maternal HIV-1 plasma viral load at delivery is the most important predictor of vertical transmission. For this reason, efforts to interrupt transmission have focused on the use of antiretroviral therapy. Zidovudine has been shown to reduce significantly vertical HIV transmission when used antepartum and intrapartum by the mother and postpartum by the newborn for 6 weeks. However, zidovudine monotherapy increases the risk of developing zidovudine resistance and may jeopardize the goal of durable viral suppression and allow HIV disease progression in the mother and transmission to the infant. Potent antiretroviral therapy is now recommended for all HIV-infected pregnant women using the same criteria for non-pregnant individuals. If possible, combination antiretroviral regimens should include the use of zidovudine but not at the expense of long-term viral suppression. The use of elective Caesarean section should probably be reserved for women who fail to achieve viral suppression at the time of delivery or if indicated for obstetrical reasons. The practice of breastfeeding has been shown to diminish the long-term efficacy of perinatal antiretroviral therapy. All HIV-infected mothers should avoid breastfeeding the newborn if possible. This review summarizes major prospective and retrospective antiretroviral treatment studies in HIV-infected pregnant women. Pharmacokinetic information as it relates to pregnancy and adverse event profiles of antiretroviral agents are also discussed. The impact of recent advances in the management of HIV infection in pregnancy is discussed with regard to their feasibility in resource-poor countries.

* Correspondence address. Bronx-Lebanon Hospital Center, Department of Medicine, 8th Floor, 1650 Grand Concourse, Bronx, NY 10457, USA. Tel: + 1-718-518-5815; Fax: + 1-718-518-5829; E-mail: mcgowanjp{at}zdnetonebox.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Gen. Virol.Home page
N. Tapia, S. Franco, F. Puig-Basagoiti, C. Menendez, P. L. Alonso, H. Mshinda, B. Clotet, J. C. Saiz, and M. A. Martinez
Influence of human immunodeficiency virus type 1 subtype on mother-to-child transmission
J. Gen. Virol., March 1, 2003; 84(3): 607 - 613.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
C. Verhofstede, E. Demecheleer, N. De Cabooter, P. Gaillard, F. Mwanyumba, P. Claeys, V. Chohan, K. Mandaliya, M. Temmerman, and J. Plum
Diversity of the Human Immunodeficiency Virus Type 1 (HIV-1) env Sequence after Vertical Transmission in Mother-Child Pairs Infected with HIV-1 Subtype A
J. Virol., March 1, 2003; 77(5): 3050 - 3057.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
L. S. Von Tungeln, L. P. Hamilton, V. N. Dobrovolsky, M. E. Bishop, J. G. Shaddock, R. H. Heflich, and F. A. Beland
Frequency of Tk and Hprt lymphocyte mutants and bone marrow micronuclei in B6C3F1/Tk+/- mice treated neonatally with zidovudine and lamivudine
Carcinogenesis, September 1, 2002; 23(9): 1427 - 1432.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
A. Dorenbaum, C. K. Cunningham, R. D. Gelber, M. Culnane, L. Mofenson, P. Britto, C. Rekacewicz, M.-L. Newell, J. F. Delfraissy, B. Cunningham-Schrader, et al.
Two-Dose Intrapartum/Newborn Nevirapine and Standard Antiretroviral Therapy to Reduce Perinatal HIV Transmission: A Randomized Trial
JAMA, July 10, 2002; 288(2): 189 - 198.
[Abstract] [Full Text] [PDF]

Home page
 NeoReviewsHome page
A. K. Shetty and Y. Maldonado
HIV transmission Prevention of Perinatal HIV-1 Transmission in the United States
NeoReviews, April 1, 2001; 2(4): e83 - 93.
[Full Text]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.